Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling
Metrics: PDF 784 views | HTML 1195 views | ?
Katelyn N. Nelson1, April N. Meyer1, Clark G. Wang1 and Daniel J. Donoghue1,2
1Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, USA
2UCSD Moores Cancer Center and University of California San Diego, La Jolla, California, USA
Daniel J. Donoghue, email: firstname.lastname@example.org
Keywords: fibroblast growth factor receptor; fusion protein; glioblastoma; FGFR3-TACC3; chromosomal translocation
Abbreviations: FGFR3: Fibroblast Growth Factor Receptor 3; TACC3: Transforming Acidic Coiled-Coil Containing Protein 3
Received: August 29, 2018 Accepted: September 08, 2018 Published: September 28, 2018
Fusion proteins resulting from chromosomal translocations have been identified as oncogenic drivers in many cancers, allowing them to serve as potential drug targets in clinical practice. The genes encoding FGFRs, Fibroblast Growth Factor Receptors, are commonly involved in such translocations, with the FGFR3-TACC3 fusion protein frequently identified in many cancers, including glioblastoma, cervical cancer, bladder cancer, nasopharyngeal carcinoma, and lung adenocarcinoma among others. FGFR3-TACC3 retains the entire extracellular domain and most of the kinase domain of FGFR3, with its C-terminal domain fused to TACC3. We examine here the effects of targeting FGFR3-TACC3 to different subcellular localizations by appending either a nuclear localization signal (NLS) or a myristylation signal, or by deletion of the normal signal sequence. We demonstrate that the oncogenic effects of FGFR3-TACC3 require either entrance to the secretory pathway or plasma membrane localization, leading to overactivation of canonical MAPK/ERK pathways. We also examined the effects of different translocation breakpoints in FGFR3-TACC3, comparing fusion at TACC3 exon 11 with fusion at exon 8. Transformation resulting from FGFR3-TACC3 was not affected by association with the canonical TACC3-interacting proteins Aurora-A, clathrin, and ch-TOG. We have shown that kinase inhibitors for MEK (Trametinib) and FGFR (BGJ398) are effective in blocking cell transformation and MAPK pathway upregulation. The development of personalized medicines will be essential in treating patients who harbor oncogenic drivers such as FGFR3-TACC3.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.